Tirzepatide
Eli Lilly’s Tirzepatide Succeeds in 2 More Late-Stage Obesity Trials Ahead of FDA Decision
SG Tylor
Source – Eli Lilly Eli Lilly continues to gather strong evidence supporting the effectiveness of tirzepatide, its dual GIP/GLP-1 agonist, ...
Lilly’s SURMOUNT-2 Study Shows Tirzepatide Achieves Significant 15.7% Weight Reduction in Adults with Obesity and Type 2 Diabetes
SG Tylor
Source – Eli Lilly On June 24, 2023, Eli Lilly and Company’s tirzepatide showed promising results in the SURMOUNT-2 Phase ...
